A biotech partnership is using AI to hunt for a drug that protects muscle from the very treatments meant to help people lose weight.
GLP-1 drugs have reshaped how millions of people approach weight loss, but the results come with a lesser-known tradeoff. Alongside fat loss, patients on these drugs often lose meaningful amounts of lean muscle mass, a side effect that matters more than it might sound. Muscle isn’t just about strength; it’s a key driver of metabolic health, mobility, and the physical resilience that determines how well someone ages. Losing it alongside fat can leave patients lighter on the scale but functionally weaker, a tradeoff that’s become one of the more pressing open problems in metabolic medicine.
That’s the gap NorthStrive Biosciences, a subsidiary of PMGC Holdings, is trying to close, and this week the company outlined its next move. NorthStrive has expanded its partnership with Yuva Biosciences, a mitochondrial sciences company, to advance four AI-discovered drug candidates through a structured, six-month program aimed at narrowing the field down to a single lead compound [1].
How an algorithm finds a drug candidate
The compounds in question were identified using Yuva’s proprietary platform, MitoNova, which combines biological, chemical and mitochondrial-function data to flag molecules likely to influence aging-related pathways, in this case, a mitochondrial protein called ANT1 that plays a central role in how skeletal muscle cells generate and use energy. In earlier phase 3 testing, all four candidates showed statistically significant increases in ANT1 activity within human skeletal muscle cells grown in the lab.
The newly announced expansion program builds on that result with a three-phase plan. The first phase establishes standardized lab procedures for testing the compounds. The second retests them in a more mature, realistic muscle-cell model to see which candidates still perform, producing what the companies describe as ranked, go-or-no-go data for each one.
The third phase profiles the strongest remaining candidates against a broader panel of mitochondrial biomarkers, measures how much cellular energy output they generate, and builds a working theory of exactly how each drug does what it does.
The end goal, expected in roughly six months, is a single nominated lead compound, plus a backup, ready to move toward the kind of formal testing the FDA requires before a drug can enter human trials.
Widening the runway
Alongside the science, the amended agreement changes the business terms in a way that signals confidence in the program. NorthStrive’s original license with Yuva covered cardiac disease and obesity. The updated deal sharpens the definitions of both those categories and adds a right of first refusal, letting NorthStrive negotiate exclusive rights across the broader cardiometabolic disease field, one of the largest and fastest-growing categories in medicine, for one year after the current testing phase wraps.
That expansion lines up with NorthStrive’s existing pipeline. The company’s lead asset, EL-22, already takes an engineered probiotic approach to preserving muscle in patients on GLP-1 therapy, and adding a small-molecule candidate targeting ANT1 would give it a second, mechanistically distinct tool aimed at the same underlying problem: keeping muscle intact while the rest of the body changes.
Why muscle preservation is a longevity story
It’s easy to file this under weight-loss drug news and move on, but the underlying science points somewhere bigger. Sarcopenia, the age-related loss of muscle mass and strength, is one of the most consistent predictors of frailty, falls and loss of independence in older adults, entirely separate from body weight.
A drug that can protect mitochondrial function in muscle tissue doesn’t just help someone tolerate a GLP-1 regimen more comfortably; it addresses one of the core mechanisms researchers point to when they talk about why bodies lose resilience with age in the first place.
There’s no guarantee any of the four candidates makes it out the other side of this six-month program, let alone through the years of clinical testing that would follow before a drug could reach patients. The companies themselves are careful to frame the work as early and preliminary. But the approach, using AI to sift candidates faster and cheaper than traditional discovery methods, reflects a broader shift in how the biotech industry is racing to solve problems that sit squarely at the intersection of metabolic health and healthy aging. If a lead compound does emerge from this pipeline, it could offer something increasingly in demand: a way to lose weight without losing the muscle that keeps people strong and mobile decades down the line.
